By Economic Times – Favirpiravir yet to find favour with ICMR PharmaceuticalsStock Analysis, IPO, Mutual Funds, Bonds & MoreHowever, the experts were not convinced and decided not to put it in the revised treatment protocol,” a person aware of the matter told ET on condition of anonymity.Last Updated: Jul 01, 2020, 08.26 AM ISTANI“The inclusion of favipiravir was discussed in the meeting on Friday. New Delhi: Even as DCGI had approved antiviral favipiravir for restricted emergency use to treat mild to moderate Covid-19 patients, the Glenmark Pharma’s drug was not part of the treatment protocol reviewed by the Indian Council of Medical Research last week. “The inclusion of favipiravir was discussed in the meeting on Friday.

However, the experts were not convinced and decided not to put it in the revised treatment protocol,” a person aware of the matter told ET on condition of anonymity.
Commenting feature is disabled in your country/region. Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service

For more details, please visit http://gestyy.com/eqPSXh

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.